|
Mar 4
|
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
|
|
Feb 16
|
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call
|
|
Dec 4
|
Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy
|
|
Nov 29
|
Does Quanterix Corporation (QTRX) Have the Potential to Rally 33.74% as Wall Street Analysts Expect?
|
|
Oct 24
|
Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease
|
|
Oct 24
|
Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection
|
|
Oct 23
|
Quanterix (NASDAQ:QTRX) shareholders have earned a 110% return over the last year
|
|
Sep 6
|
Here's Why You Should Retain Omnicell (OMCL) Stock Now
|
|
Sep 6
|
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
|
|
Aug 9
|
Quanterix Appoints Vandana Sriram as Chief Financial Officer
|
|
Aug 7
|
Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 7
|
Quanterix Releases Operating Results for Second Quarter 2023
|
|
Apr 25
|
FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials
|